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A B S T R A C T
We assessed the clinical variables predicting the feasibility of immediate overnight switching from slow-
release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Thirty
patients aged 15 years or older with refractory partial epilepsy, who had been treated with slow-release
carbamazepine as monotherapy or in combination therapy, were switched overnight from slow-release
carbamazepine (mean dose at switching, 900 mg/day) to oxcarbazepine. Of these 30 patients, 29 (96.7%)
had been treated with a slow-release formulation of carbamazepine. The proportion of patients with
polytherapy was 85.3%. Overall, 9 of 30 (30%) switched patients experienced clinically signiﬁcant
adverse events until 2 weeks after switching, including 2 with seizure aggravation. The only clinical
variable related to the failure of overnight switching was the number of seizures at baseline.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Oxcarbazepine (OXC) is an antiepileptic drug (AED) with a
chemical structure similar to that of carbamazepine (CBZ). OXC
may have some further pharmacological actions, but the main
anticonvulsant effect is very likely due to mechanisms shared with
CBZ.1,2 In patients with inadequate seizure control on CBZ alone,
switching to OXC or adding OXC to CBZ has been shown to be
effective in controlling.3–5
To avoid increasing the overall drug burden of a patient,
substitution therapy has been regarded as preferable to add-on
therapy. Although physicians generally choose to switch patients
progressively from one AED to another, CBZ and OXCmay be safely
substituted for each other overnight.6–8 In a trial conducted by
Albani et al.,9 90% of patients experienced no clinically signiﬁcant
adverse events after overnight switching, indicating that overnightAbbreviations: OXC, oxcarbazepine; AED, antiepileptic drug; CBZ, carbamazepine.
* Corresponding author at: Department of Neurology, Yonsei University College
of Medicine, Severance Hospital, 134 Sinchon-dong, Seodaemun-gu, Seoul 120-752,
Republic of Korea. Tel.: +82 2 2228 1600.
E-mail address: bilee@yuhs.ac (B.-I. Lee).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.05.002switching is as well tolerated as is progressive switching and that
overnight switching from CBZ to OXCwas feasible inmost patients
on polytherapy.9
In investigating the therapeutic efﬁcacy of immediate over-
night switching from slow-release CBZ to OXC in patients with
refractory partial epilepsy, we found that a large proportion of
patients experienced intolerable side effects, leading to early
termination of our study. We reviewed these results to identify
clinical variables predicting the feasibility of overnight switching
from slow-release CBZ to OXC in Korean patients with refractory
partial epilepsy.
2. Methods
2.1. Patients
Patients aged 15 years with a diagnosis of partial epilepsy
were recruited. Subjects were included if they had at least three
seizures during a baseline period and were being treated with at
least 400 mg/day CBZ, either as monotherapy or as combination
therapy (maximum, three AEDs). Patients were excluded if they
had been exposed previously to OXC, if they experienced statusvier Ltd. All rights reserved.
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relevant medical illness or signiﬁcant psychiatric disorder.
The studywas approved by our local ethics committees andwas
conducted in accordance with Good Clinical Practice and the
Declaration of Helsinki. Each participant gave written informed
consent.
2.2. Study design
This was an observational, multicenter, open-label, single-arm
study. The study consisted of a 12-week baseline and a 12-week
treatment phase. Unless seizure type and frequency could be
obtained retrospectively from a patient diary, patients entered the
prospective baseline phase.
At the end of the baseline phase, patients were switched from
slow-release CBZ to OXC overnight. The conversion ratio
(CBZ:OXC) was 1:1.5 for slow-release CBZ doses of 400–800 mg/
day. However, because of autoinduction with CBZ at doses greater
than 1000 mg/day, a reduced ratio of 1:1.2 was used for slow-
release CBZ doses of 900–1600 mg/day. There were three
scheduled visits, after 2, 6, and 12 weeks of treatment. The dose
of OXC could be optimized based on individual tolerability and
seizure control during the study from the next day after overnight
switch. However, no dose adjustment of any associated AED was
allowed during the study.Table 1
Baseline characteristics of patients undergoing immediate overnight switching from ca
Patients with C
Age, mean years (SD) 38.7 (9.1)
Male (%) 3 (33.3)
Duration of epilepsy, mean years (SD) 19.2 (10.6)
*Total seizures during the baseline period, mean (SD) 10.3 (8.0)
Generalized seizures during the baseline period, mean (SD) 0.33 (1.00)
Etiology of epilepsy, symptomatic:cryptogenic 3:6
Type of seizures
Simple partial 0
Complex partial 8
Partial to secondary generalization 1
Type of carbamazepine received
Regular form 0
Slow-release form 9
Last daily dosage of carbamazepine, mean mg (range) 933 (600–120
Last daily dosage of carbamazepine
800mg 5 (26.3%)
1000mg 4 (36.4%)
Initial daily dosage of oxcarbazepine, mean mg (range) 1266 (600–150
Initial daily dosage of oxcarbazepine
900mg 1 (25%)
1200mg 5 (29.4%)
1500mg 3 (33.3%)
Antiepileptic drugs
carbamazepine monotherapy 3
carbamazepine plus one AED 4
carbamazepine plus two AEDs 2
Co-antiepileptic drugs
Topiramate 1
Levetiracetam 2
Pregabalin 2
Zonisamide 3
Valproic acid 0
Phenobarbital 0
Clonazepam 0
Lamotrigine 0
Patients receiving non-AED concomitant medications, n 3
CSAE, clinically signiﬁcant adverse events; SD, standard deviation; AED, antiepileptic d2.3. Assessments
We assessed the proportion of patients who experienced any
clinically signiﬁcant adverse event during the 2 weeks after the
switch. Such events were deﬁned as events that required speciﬁc
medical intervention or led to modiﬁcation or interruption of OXC
therapy. Clinical variables predicting the clinical feasibility of
overnight switching were evaluated.
2.4. Statistical analysis
The occurrence of clinically signiﬁcant adverse events was
correlated with clinical variables using Fisher’s exact test and the
Mann–Whitney U-test. P-values less than 0.05 were considered
statistically signiﬁcant. Data were analyzed using SPSS version
12.0 (SPSS Inc., Chicago, IL).
3. Results
Of a total of 33 patients enrolled, 30 underwent a switch from
slow-release CBZ to OXC. Three patients dropped out before the
switch because of violations of inclusion criteria. The baseline
characteristics of all switched patients are shown in Table 1. Of the
30 patients, 29 (96.7%) were being treated with a slow-release
formulation of CBZ, and 25 (83.3%) were being treated withrbamazepine to oxcarbazepine.
SAE (n=9) Patients without CSAE (n=21) Total (n=30)
38.9 (11.8) 38.8 (10.9)
9 (42.9) 12 (40)
18.7 (9.9) 18.9 (9.9)
6.7 (5.5) 7.8 (6.4)
0.62 (1.36) 0.53 (1.25)
13:8 16:14
4 4 (13.4%)
12 20 (66.7%)
5 6 (20.0%)
1 1
20 29
0) 885 (400–1200) 900 (400–1200)
14 (73.7%) 19 (63.3%)
7 (63.6%) 11 (36.7%)
0) 1228 (600–1500) 1240 (600–1500)
3 (75%) 4 (13.3%)
12 (70.6%) 17 (56.7%)
6 (66.7%) 9 (30.0%)
2 5 (16.7%)
12 16 (55.3%)
7 9 (30%)
9 10
7 9
3 5
0 3
5 5
2 2
1 1
1 1
7 10 (33.3%)
rug.
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900 mg/day (range, 400–1200 mg/day).
Overall, 9 (30%) of 30 switched patients experienced clinically
signiﬁcant adverse events during the ﬁrst 2 weeks after switching;
of these, 2 experienced seizure aggravation, and 7 experienced side
effects (vertigo, headache, diplopia, somnolence, insomnia, skin
rashes, and a tingling sensation). All these patients discontinued
the study. An additional ﬁve patients (16.7%) dropped out during
the 2–12 weeks after a switch; four because of seizure aggravation
and one who was lost to follow-up. Sixteen (53.3%) of the 30
patients successfully completed the study, to 12 weeks after
switching. Among these, ﬁve patients experienced seizure reduc-
tion of over 50%.
The ﬁnal slow-release CBZ or initial OXC dosages did not differ
signiﬁcantly between patients who successfully switched and
those who failed switching. The only clinical variable related to the
occurrence of clinically signiﬁcant adverse events was the number
of seizures during the 12-week baseline period, which was
signiﬁcantly higher in those with adverse events than those
without them (10.3 vs. 6.7, P < 0.05). The number of seizures
during baseline period was not signiﬁcantly related to the ﬁnal
slow-release CBZ, initial OXC dosages, or the number of antiepi-
leptic drugs.
4. Discussion
Immediate overnight switching from CBZ to OXC has been
suggested to be safe,8–10 with about 90% of patients experiencing
no clinically signiﬁcant adverse events, indicating that immediate
overnight switching appears feasible in most patients on mono-
therapy or polytherapy.8,9 In contrast, we found that 30% of
patients experienced clinically signiﬁcant adverse events after
overnight switching and that all of these patients discontinued the
study.
In this study, the only clinical variable related to the occurrence
of clinically signiﬁcant adverse events was the number of seizures
during the baseline period, which was signiﬁcantly higher in those
with adverse events than those without them. But our patients
with more frequent seizures did not have higher dosage of slow-
release CBZ and/or take on polytherapy, which might be
contributing to failure rate of overnight switching.
Several potential factors may explain these differences
between studies in the proportion of patients experiencing
adverse events after overnight switching. One is the ﬁnal dosage
of slow-release CBZ before switching. Although the CBZ dosages
did not differ signiﬁcantly between patients who failed switch-
ing and those who successfully switched in this study, we
cannot exclude the possibility of small sample size effects.
Comparing to CBZ dose (mean 786 mg/day) in a previous study,8
a mean slow-release CBZ dose (900 mg/day) in this study was
higher. So it is possible that a higher slow-release CBZ dosage
prior to switching may have contributed to the greater rate of
switch failures.
Another factor that may have contributed to the difference
between studies was AED polytherapy. The proportion of patients
on polytherapy was higher in our study than in a previous study
(83.3% vs. 47.1%).9 Because of the possibility of an enhanced level of
adverse events after overnight switching in patients receiving
polytherapy compared to those on monotherapy, it has been
recommended that the former class of patients be gradually
switched over 2–3 weeks.1,5 Other potential factors affecting the
occurrence of adverse events after switching may be the use of
concomitant drugs that induce or inhibit hepatic enzymes.11 This
factor, however, was not likely to affect our results because none ofour patients who failed switching had been treated with hepatic
enzyme-inducing or -inhibiting drugs.
Because of pharmacokinetic differences, a CBZ:OXZ conversion
ratio of 1:1–1.2 is generally recommended for replacement of the
slow-release formulation of CBZ, whereas a conversion ratio of
1:1.5 is recommended when the conventional formulation of CBZ
is employed.2,8,11 Almost all of our patients (96.7%) were being
treated with a slow-release formulation of CBZ prior to switching,
compared with 56.6% and 60% of patients in previous studies,8,9
suggesting a relationship between the higher proportion of
patients taking the slow-release formulation of CBZ and the
elevated rate of switch-failed patients in the present study.
Finally, ethnic differences cannot be excluded. A certain
proportion of patients may experience increased side effects
during a switch, especially an overnight switch. This is thought to
be attributable to variation in CBZ autoinduction from patient to
patient. Using equivalent doses of OXC in such a situation is clearly
inappropriate. Because of autoinduction with CBZ at doses greater
than 800 mg/day, a slightly lower ratio has been recommended,
thus, 1:1.2 to 1:1.4.1 This variability in CBZ autoinduction may be
inﬂuenced by ethnic differences.
Although clinical experience supports the feasibility of an
overnight switch from CBZ to OXC, a gradual conversion scheme
has been recommended, by initiating OXC at 150 mg b.i.d., and
titrating upwards by 150 mg every 2 days.1 This switch method
remains rapid and ensures that patients achieve seizure control
quickly. CBZ dosage should be reduced by 25% prior to titration of
OXC, to avoid problems of increased drug load, which may lead to
an increase in tolerability problems.
5. Conclusion
Patients with a higher baseline seizure frequency may be at
higher risk of failure of immediate overnight switching from slow-
release CBZ to OXC.
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